Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease

Area of Science:

• Cardiology
• Pharmacology
• Vascular Biology

Background:

• Angiotensin-converting enzyme (ACE) inhibitors are standard treatments for heart failure, diabetic complications, and post-myocardial infarction recovery.
• Angiotensin II and bradykinin influence cellular proliferation, inflammation, and endothelial function, key factors in atherosclerosis development.
• Experimental data suggest ACE inhibitors can mitigate these pro-atherosclerotic effects.

Purpose of the Study:

• To evaluate the clinical efficacy of ACE inhibitors in managing atherosclerotic vascular disease.
• To determine if ACE inhibition offers prognostic benefits beyond its established cardiovascular and renal effects.

Main Methods:

• Clinical trials were designed to assess the impact of ACE inhibitors on patient prognosis.
• Study populations included patients with existing or at-risk atherosclerotic vascular disease.

Main Results:

• The initial clinical trial demonstrated that ACE inhibition significantly improves prognosis in patients with atherosclerotic vascular disease.
• This improvement was observed independently of ACE inhibitors' effects on left ventricular function and hypertension.

Conclusions:

• ACE inhibition is beneficial for patients with atherosclerotic vascular disease, irrespective of left ventricular function or hypertension.
• Evidence supports expanding the indications for ACE inhibitors in cardiovascular medicine.
• Further research is needed to identify the optimal ACE inhibitor for these expanded indications.